Developments and future clinical outlook of taxane nanomedicines

Benoit Louage, Olivier De Wever, Wim E. Hennink, Bruno G. De Geest*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Taxanes are highly valuable drugs for cancer treatment. Low water-solubility however puts a major challenge in obtaining formulations that are stable and easy-to-use in clinical practice. Initially, solubilization and lowering toxicity of taxanes has been the main research focus. However, emerging passive and active targeting strategies, especially in the field of nanomedicine, have been capital incentives to further broaden therapeutic index by improving efficacy. This review provides an up-to-date clinical track record of taxane nanomedicines in view of the current state-of-the-art in anti-cancer drug delivery. Additionally, the clinical status of taxane nanomedicines is discussed and considerations are provided for improving future clinical translation.

Original languageEnglish
Pages (from-to)137-152
Number of pages16
JournalJournal of Controlled Release
Volume253
DOIs
Publication statusPublished - 10 May 2017

Keywords

  • Cancer
  • Conjugates
  • Nanomedicine
  • Nanoparticles
  • Paclitaxel

Fingerprint

Dive into the research topics of 'Developments and future clinical outlook of taxane nanomedicines'. Together they form a unique fingerprint.

Cite this